Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| 1 |
Berkshire Hathaway Class B
BRK.B
|
+$1.6B |
| 2 |
American Express
AXP
|
+$398M |
| 3 |
Capital One
COF
|
+$151M |
| 4 |
Apollo Global Management
APO
|
+$111M |
| 5 |
DFS
Discover Financial Services
DFS
|
+$109M |
Top Sells
| 1 |
Apple
AAPL
|
+$1.16B |
| 2 |
Microsoft
MSFT
|
+$873M |
| 3 |
Amazon
AMZN
|
+$403M |
| 4 |
NVIDIA
NVDA
|
+$356M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$283M |
Sector Composition
| 1 | Technology | 30.21% |
| 2 | Healthcare | 13.75% |
| 3 | Consumer Discretionary | 12.04% |
| 4 | Industrials | 9.22% |
| 5 | Communication Services | 8.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Carter's
CRI
$1.08B
| $5.98M | ﹤0.01% |
82,400
| – | – |
|
|
NARI
1202
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $5.98M | ﹤0.01% |
102,800
+10,100
| +11% | +$587K |
|
|
ENLC
1203
DELISTED
ENLINK MIDSTREAM, LLC
ENLC
| $5.97M | ﹤0.01% |
563,623
+1,400
| +0.2% | +$14.8K |
|
1204
Transmedics
TMDX
$3.91B
| $5.95M | ﹤0.01% |
70,900
+5,400
| +8% | +$453K |
|
1205
Methanex
MEOH
$3.04B
| $5.95M | ﹤0.01% |
143,900
+22,100
| +18% | +$914K |
|
1206
Cactus
WHD
$2.74B
| $5.94M | ﹤0.01% |
140,300
+9,300
| +7% | +$394K |
|
1207
Carpenter Technology
CRS
$12B
| $5.93M | ﹤0.01% |
105,600
+1,100
| +1% | +$61.7K |
|
1208
Plexus
PLXS
$3.73B
| $5.92M | ﹤0.01% |
60,300
+600
| +1% | +$58.9K |
|
1209
Sabra Healthcare REIT
SBRA
$4.57B
| $5.92M | ﹤0.01% |
503,241
+4,700
| +0.9% | +$55.3K |
|
1210
Acadia Pharmaceuticals
ACAD
$3.98B
| $5.92M | ﹤0.01% |
247,304
-14,800
| -6% | -$354K |
|
1211
Rapid7
RPD
$1.27B
| $5.92M | ﹤0.01% |
130,700
+2,900
| +2% | +$131K |
|
1212
CNO Financial Group
CNO
$3.8B
| $5.92M | ﹤0.01% |
250,000
+3,000
| +1% | +$71K |
|
1213
Core & Main
CNM
$9.28B
| $5.9M | ﹤0.01% |
188,400
+39,700
| +27% | +$1.24M |
|
1214
PTC Therapeutics
PTCT
$4.85B
| $5.88M | ﹤0.01% |
144,665
+5,100
| +4% | +$207K |
|
1215
Prothena Corp
PRTA
$442M
| $5.87M | ﹤0.01% |
85,900
+12,800
| +18% | +$874K |
|
1216
OR Royalties Inc.
OR
$6.76B
| $5.85M | ﹤0.01% |
380,230
| – | – |
|
1217
Flywire
FLYW
$1.63B
| $5.85M | ﹤0.01% |
188,400
+120,800
| +179% | +$3.75M |
|
1218
ESCO Technologies
ESE
$5.38B
| $5.82M | ﹤0.01% |
56,200
+400
| +0.7% | +$41.5K |
|
1219
COPT Defense Properties
CDP
$3.46B
| $5.82M | ﹤0.01% |
245,000
+2,300
| +0.9% | +$54.6K |
|
1220
Artisan Partners
APAM
$3.27B
| $5.81M | ﹤0.01% |
147,900
+1,300
| +0.9% | +$51.1K |
|
1221
Amicus Therapeutics
FOLD
$2.46B
| $5.8M | ﹤0.01% |
461,600
+6,800
| +1% | +$85.4K |
|
1222
Werner Enterprises
WERN
$1.68B
| $5.79M | ﹤0.01% |
131,100
+8,300
| +7% | +$367K |
|
1223
RingCentral
RNG
$2.75B
| $5.79M | ﹤0.01% |
176,900
+700
| +0.4% | +$22.9K |
|
|
AYX
1224
DELISTED
Alteryx, Inc.
AYX
| $5.79M | ﹤0.01% |
127,500
-4,600
| -3% | -$209K |
|
1225
Alight
ALIT
$1.95B
| $5.77M | ﹤0.01% |
624,700
+73,400
| +13% | +$678K |
|